Pfizer (NYSE:PFE) Shares Up 0.4%

Pfizer Inc. (NYSE:PFEGet Free Report)’s stock price shot up 0.4% during mid-day trading on Tuesday . The company traded as high as $28.33 and last traded at $28.17. 7,102,847 shares were traded during trading, a decline of 83% from the average session volume of 41,571,469 shares. The stock had previously closed at $28.07.

Analyst Ratings Changes

Several equities research analysts have weighed in on PFE shares. Morgan Stanley increased their price objective on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from, Pfizer presently has an average rating of “Hold” and an average price target of $35.86.

View Our Latest Stock Report on PFE

Pfizer Trading Down 0.2 %

The stock has a market cap of $158.72 billion, a PE ratio of -469.42, a PEG ratio of 1.12 and a beta of 0.70. The stock’s fifty day moving average price is $27.51 and its 200 day moving average price is $27.83. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFEGet Free Report) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The business had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the company earned $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of PFE. Clifford Swan Investment Counsel LLC increased its holdings in shares of Pfizer by 4.7% in the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after buying an additional 18,611 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the period. LifePlan Financial LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at about $255,000. Cantor Fitzgerald Investment Advisors L.P. purchased a new position in shares of Pfizer in the 4th quarter worth approximately $16,166,000. Finally, KLCM Advisors Inc. lifted its position in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after acquiring an additional 74,487 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.